Webinar Announcement: Biomarkers Can’t Wait – Accelerating the Path to CMT Treatments
Biomarkers are essential to developing effective treatments—but in Charcot–Marie–Tooth (CMT), the lack of validated biomarkers remains a major barrier to progress. Without reliable ways to measure change over time, clinical trials take longer, cost more, and may fail to clearly show whether a therapy is working.
This webinar brings together experts, researchers, clinicians, and patient advocates to explore why better measurement is foundational to faster, more successful drug development in CMT. The session will examine current challenges in biomarker discovery and validation, the promise of blood-based biomarkers and digital health technologies, and why less invasive, scalable tools are critical for inclusive, global clinical trials.
Participants will also learn how the Hereditary Neuropathy Foundation (HNF) is building the infrastructure needed to support biomarker development and clinical trial readiness—through integrated patient data, biospecimen collection, and real-world functional measures.
Whether you are a patient or caregiver seeking to understand how research moves forward, or a researcher or industry partner working to advance CMT therapies, this webinar will provide valuable insight into how biomarkers can accelerate progress and bring treatments closer to the people who need them.
Webinar Details
📅 Tuesday, January 20, 2026
⏰ 12:30 PM Eastern Time (US & Canada)
📍 Virtual
We hope you’ll join us as we work together to move CMT science—and treatments—forward.
0 Comments